Mozart Therapeutics , a leading developer of CD8 Treg modulators in autoimmune and inflammatory disease, today announced the presentation of data at the American Association of Immunologists (AAI) Annual Meeting.
| SEATTLE, May 10, 2022 /PRNewswire/ -- Mozart Therapeutics, a leading developer of CD8 Treg modulators in autoimmune and inflammatory disease, today announced the presentation of data at the American Association of Immunologists (AAI) Annual Meeting identifying the potential role of a novel CD8 T regulatory cell network in celiac disease and other autoimmune disorders, and the potential of targeted, bispecific CD8 Treg modulators as a new therapeutic treatment approach.
Mozart researchers presented preclinical findings supporting a key role of the CD8 T regulatory cell network in the surveillance and elimination of disease-causing CD4 T cells that are a root cause for autoimmune and inflammatory disease. Preclinical in vitro, in vivo and human ex vivo data revealed the potential of targeted bispecific CD8 Treg modulators to activate the CD8 T regulatory cell network resulting in the elimination of pathogenic CD4 T cells, the reduction of an inflammatory response and the amelioration of disease. “Our presentations at AAI elucidate the CD8 Treg cell network in celiac disease and many other autoimmune diseases and support the potential of bispecific CD8 Treg modulators as novel, selective and potentially broadly applicable therapeutics,” said Kristine Swiderek, PhD, Chief Scientific Officer at Mozart Therapeutics. “CD8 Treg Modulators offer a promising treatment approach as disease modifying therapeutic molecules that selectively target the CD8 regulatory T cell network to counteract early events in the autoimmune inflammatory cascade.” Presentation details and link to poster presentations are as follows: Abstract #: 1090 Abstract #: 889 About Mozart Therapeutics About CD8 Treg Modulators Media Contact:
SOURCE Mozart Therapeutics |
View original content to download multimedia:
